Medicines Discovery Catapult and the Medical Research Council Centre for Drug Safety Science at the University of Liverpool are collaborating.
They have agreed a memorandum of understanding to combine their academic and industry expertise in developing next generation 3D human cell models and creating robust cellular platforms.
Through the collaboration these will be available to UK drug discovery SMEs.
The first project to be undertaken under the new alliance will focus on the development of a next generation cardiac safety model. The human cell model will enable companies to measure a broader range of patient relevant toxicities in a single assay.
Picture credit | Science Photo Library
